122 related articles for article (PubMed ID: 38012293)
1. Author Correction: DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2024 Mar; 45(3):660. PubMed ID: 38012293
[No Abstract] [Full Text] [Related]
2. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2021 Jan; 42(1):132-141. PubMed ID: 32404982
[TBL] [Abstract][Full Text] [Related]
3. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
4. PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer.
Chai Z; Wang L; Zheng Y; Liang N; Wang X; Zheng Y; Zhang Z; Zhao C; Zhu T; Liu C
Cancer Cell Int; 2019; 19():277. PubMed ID: 31708688
[TBL] [Abstract][Full Text] [Related]
5. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitor gedunin causes apoptosis in A549 lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and downregulating autophagy.
Hasan A; Haque E; Hameed R; Maier PN; Irfan S; Kamil M; Nazir A; Mir SS
Life Sci; 2020 Sep; 256():118000. PubMed ID: 32585246
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells.
Qiu C; Shen X; Lu H; Chen Y; Xu C; Zheng P; Xia Y; Wang J; Zhang Y; Li S; Zou P; Cui R; Chen J
Cell Death Discov; 2023 Oct; 9(1):375. PubMed ID: 37833257
[TBL] [Abstract][Full Text] [Related]
8. Ultrafast Low-Temperature Photothermal Therapy Activates Autophagy and Recovers Immunity for Efficient Antitumor Treatment.
Deng X; Guan W; Qing X; Yang W; Que Y; Tan L; Liang H; Zhang Z; Wang B; Liu X; Zhao Y; Shao Z
ACS Appl Mater Interfaces; 2020 Jan; 12(4):4265-4275. PubMed ID: 31903741
[TBL] [Abstract][Full Text] [Related]
9. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.
Cheng CJ; Liu KX; Zhang M; Shen FK; Ye LL; Wu WB; Hou XT; Hao EW; Hou YY; Bai G
Acta Pharmacol Sin; 2022 Apr; 43(4):1046-1058. PubMed ID: 34326484
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
11. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response.
Liu P; Chen X; Zhu J; Li B; Chen Z; Wang G; Sun H; Xu Z; Zhao Z; Zhou C; Xie C; Lou L; Zhu W
ChemistryOpen; 2019 Mar; 8(3):344-353. PubMed ID: 30976475
[TBL] [Abstract][Full Text] [Related]
13. 3'-epi-12β-hydroxyfroside, a new cardenolide, induces cytoprotective autophagy via blocking the Hsp90/Akt/mTOR axis in lung cancer cells.
Sun Y; Huang YH; Huang FY; Mei WL; Liu Q; Wang CC; Lin YY; Huang C; Li YN; Dai HF; Tan GH
Theranostics; 2018; 8(7):2044-2060. PubMed ID: 29556372
[No Abstract] [Full Text] [Related]
14. Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2024 May; 30(5):1503. PubMed ID: 38570701
[No Abstract] [Full Text] [Related]
15. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer cells.
Pan Z; Chen Y; Pang H; Wang X; Zhang Y; Xie X; He G
Eur J Med Chem; 2022 Nov; 242():114674. PubMed ID: 35987020
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells.
Wang B; Chen L; Ni Z; Dai X; Qin L; Wu Y; Li X; Xu L; Lian J; He F
Exp Cell Res; 2014 Nov; 328(2):379-87. PubMed ID: 25196280
[TBL] [Abstract][Full Text] [Related]
20. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
